Metastatic breast cancer treated with lapatinib with a prolonged benefit: a case report and a review of therapeutic options available

Tumori. 2013 Nov-Dec;99(6):269e-72e. doi: 10.1700/1390.15466.

Abstract

A 53-year-old woman was treated, after trastuzumab progression of HER2-positive metastatic disease, with capecitabine plus lapatinib and subsequently with lapatinib alone. To date, she has had persistent remission of disease since 2009.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Breast Neoplasms / chemistry
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology*
  • Capecitabine
  • Carcinoma, Ductal, Breast / chemistry
  • Carcinoma, Ductal, Breast / drug therapy*
  • Carcinoma, Ductal, Breast / secondary
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives
  • Disease-Free Survival
  • Drug Administration Schedule
  • Female
  • Fluorouracil / administration & dosage
  • Fluorouracil / analogs & derivatives
  • Humans
  • Lapatinib
  • Letrozole
  • Lymphatic Metastasis
  • Middle Aged
  • Molecular Targeted Therapy / methods
  • Nitriles / administration & dosage
  • Paclitaxel / administration & dosage
  • Protein Kinase Inhibitors / administration & dosage
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Quality of Life
  • Quinazolines / administration & dosage
  • Receptor, ErbB-2 / analysis
  • Receptor, ErbB-2 / drug effects*
  • Trastuzumab
  • Treatment Outcome
  • Triazoles / administration & dosage

Substances

  • Antibodies, Monoclonal, Humanized
  • Nitriles
  • Protein Kinase Inhibitors
  • Quinazolines
  • Triazoles
  • Lapatinib
  • Deoxycytidine
  • Capecitabine
  • Letrozole
  • ERBB2 protein, human
  • Protein-Tyrosine Kinases
  • Receptor, ErbB-2
  • Trastuzumab
  • Paclitaxel
  • Fluorouracil